AU2020372002A1 - Mettl3 modulators - Google Patents
Mettl3 modulators Download PDFInfo
- Publication number
- AU2020372002A1 AU2020372002A1 AU2020372002A AU2020372002A AU2020372002A1 AU 2020372002 A1 AU2020372002 A1 AU 2020372002A1 AU 2020372002 A AU2020372002 A AU 2020372002A AU 2020372002 A AU2020372002 A AU 2020372002A AU 2020372002 A1 AU2020372002 A1 AU 2020372002A1
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- cycloalkyl
- compound
- halo
- membered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 101150084627 Mettl3 gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 222
- 150000003839 salts Chemical class 0.000 claims abstract description 141
- 238000000034 method Methods 0.000 claims abstract description 24
- -1 C1-6alkenyl Chemical group 0.000 claims description 192
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 160
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 152
- 125000005843 halogen group Chemical group 0.000 claims description 139
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 119
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 115
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 105
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 60
- 125000001424 substituent group Chemical group 0.000 claims description 60
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 51
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 48
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 47
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 39
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 38
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 36
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 34
- 229910052757 nitrogen Inorganic materials 0.000 claims description 34
- 125000005842 heteroatom Chemical group 0.000 claims description 33
- 229910052760 oxygen Inorganic materials 0.000 claims description 33
- 102100040619 N6-adenosine-methyltransferase catalytic subunit Human genes 0.000 claims description 32
- 101000967135 Homo sapiens N6-adenosine-methyltransferase catalytic subunit Proteins 0.000 claims description 31
- 125000001072 heteroaryl group Chemical group 0.000 claims description 31
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 29
- 229910052717 sulfur Inorganic materials 0.000 claims description 29
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 27
- 125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 claims description 24
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 23
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 22
- 230000000694 effects Effects 0.000 claims description 17
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 claims description 16
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 14
- 208000035475 disorder Diseases 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 13
- MROJXXOCABQVEF-UHFFFAOYSA-N Actarit Chemical compound CC(=O)NC1=CC=C(CC(O)=O)C=C1 MROJXXOCABQVEF-UHFFFAOYSA-N 0.000 claims description 12
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 12
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims description 12
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 11
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 11
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 claims description 10
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 10
- 229910052794 bromium Inorganic materials 0.000 claims description 10
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims description 8
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 229910052731 fluorine Inorganic materials 0.000 claims description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 7
- KDOPAZIWBAHVJB-UHFFFAOYSA-N 5h-pyrrolo[3,2-d]pyrimidine Chemical compound C1=NC=C2NC=CC2=N1 KDOPAZIWBAHVJB-UHFFFAOYSA-N 0.000 claims description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 6
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 6
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 208000036142 Viral infection Diseases 0.000 claims description 5
- 125000002393 azetidinyl group Chemical group 0.000 claims description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 5
- 125000002541 furyl group Chemical group 0.000 claims description 5
- 230000005764 inhibitory process Effects 0.000 claims description 5
- 125000002757 morpholinyl group Chemical group 0.000 claims description 5
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 5
- 230000009385 viral infection Effects 0.000 claims description 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 4
- FNQJDLTXOVEEFB-UHFFFAOYSA-N 1,2,3-benzothiadiazole Chemical compound C1=CC=C2SN=NC2=C1 FNQJDLTXOVEEFB-UHFFFAOYSA-N 0.000 claims description 4
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 claims description 4
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 claims description 4
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 claims description 4
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims description 4
- ZKAMEFMDQNTDFK-UHFFFAOYSA-N 1h-imidazo[4,5-b]pyrazine Chemical compound C1=CN=C2NC=NC2=N1 ZKAMEFMDQNTDFK-UHFFFAOYSA-N 0.000 claims description 4
- AMFYRKOUWBAGHV-UHFFFAOYSA-N 1h-pyrazolo[4,3-b]pyridine Chemical compound C1=CN=C2C=NNC2=C1 AMFYRKOUWBAGHV-UHFFFAOYSA-N 0.000 claims description 4
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 claims description 4
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 claims description 4
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 claims description 4
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 4
- RXQZLSRIOOYKLF-UHFFFAOYSA-N 5H-pyrazolo[4,3-d]triazine Chemical compound N1=NN=C2C=NNC2=C1 RXQZLSRIOOYKLF-UHFFFAOYSA-N 0.000 claims description 4
- MJQSRSOTRPMVKB-UHFFFAOYSA-N 5h-imidazo[4,5-c]pyridazine Chemical compound C1=NNC2=NC=NC2=C1 MJQSRSOTRPMVKB-UHFFFAOYSA-N 0.000 claims description 4
- 239000005964 Acibenzolar-S-methyl Substances 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- NABZXASCLFSKLF-UHFFFAOYSA-N [1,2]oxazolo[4,3-b]pyridine Chemical compound C1=CC=NC2=CON=C21 NABZXASCLFSKLF-UHFFFAOYSA-N 0.000 claims description 4
- YJMPFOXUBAJFFA-UHFFFAOYSA-N [1,2]thiazolo[4,3-b]pyridine Chemical compound C1=CC=NC2=CSN=C21 YJMPFOXUBAJFFA-UHFFFAOYSA-N 0.000 claims description 4
- BFPLMTPHDFFMTG-UHFFFAOYSA-N [1,3]oxazolo[5,4-b]pyridine Chemical compound C1=CN=C2OC=NC2=C1 BFPLMTPHDFFMTG-UHFFFAOYSA-N 0.000 claims description 4
- WFIHKLWVLPBMIQ-UHFFFAOYSA-N [1,3]thiazolo[5,4-b]pyridine Chemical compound C1=CN=C2SC=NC2=C1 WFIHKLWVLPBMIQ-UHFFFAOYSA-N 0.000 claims description 4
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 4
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 claims description 4
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 claims description 4
- 239000012964 benzotriazole Substances 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical compound C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 claims description 4
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 claims description 4
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 claims description 4
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 claims description 4
- YEYHFKBVNARCNE-UHFFFAOYSA-N pyrido[2,3-b]pyrazine Chemical compound N1=CC=NC2=CC=CN=C21 YEYHFKBVNARCNE-UHFFFAOYSA-N 0.000 claims description 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010027406 Mesothelioma Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- DBDCNCCRPKTRSD-UHFFFAOYSA-N thieno[3,2-b]pyridine Chemical compound C1=CC=C2SC=CC2=N1 DBDCNCCRPKTRSD-UHFFFAOYSA-N 0.000 claims description 2
- 239000002175 thienopyridine Substances 0.000 claims description 2
- 229940125670 thienopyridine Drugs 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 description 103
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 86
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 75
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 67
- 230000015572 biosynthetic process Effects 0.000 description 66
- 238000003786 synthesis reaction Methods 0.000 description 66
- 238000006243 chemical reaction Methods 0.000 description 54
- 239000000243 solution Substances 0.000 description 54
- 229910001868 water Inorganic materials 0.000 description 53
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 46
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 38
- 239000007787 solid Substances 0.000 description 35
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 33
- 125000003118 aryl group Chemical group 0.000 description 31
- 125000000217 alkyl group Chemical group 0.000 description 30
- 125000004432 carbon atom Chemical group C* 0.000 description 29
- 150000001412 amines Chemical class 0.000 description 27
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 25
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 23
- 125000004404 heteroalkyl group Chemical group 0.000 description 22
- 239000012044 organic layer Substances 0.000 description 22
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 20
- 239000002904 solvent Substances 0.000 description 20
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 18
- 125000004122 cyclic group Chemical group 0.000 description 18
- 239000011541 reaction mixture Substances 0.000 description 17
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 16
- 150000004820 halides Chemical class 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 125000006239 protecting group Chemical group 0.000 description 16
- 125000002619 bicyclic group Chemical group 0.000 description 15
- 235000019439 ethyl acetate Nutrition 0.000 description 15
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 15
- 125000000623 heterocyclic group Chemical group 0.000 description 15
- 239000012043 crude product Substances 0.000 description 14
- 239000012071 phase Substances 0.000 description 14
- 239000007832 Na2SO4 Substances 0.000 description 13
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 13
- 239000012267 brine Substances 0.000 description 13
- 125000002950 monocyclic group Chemical group 0.000 description 13
- 229910052938 sodium sulfate Inorganic materials 0.000 description 13
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 13
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 13
- 238000005160 1H NMR spectroscopy Methods 0.000 description 11
- 239000000377 silicon dioxide Substances 0.000 description 11
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 11
- 230000009466 transformation Effects 0.000 description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- HSHYLYNZXWHCOK-VMXABPDPSA-N C(=C)[C@H]1C[C@@H]([C@H]2[C@@H]1OC(O2)(C)C)N1C=C(C2=C1N=CN=C2Cl)C=O Chemical compound C(=C)[C@H]1C[C@@H]([C@H]2[C@@H]1OC(O2)(C)C)N1C=C(C2=C1N=CN=C2Cl)C=O HSHYLYNZXWHCOK-VMXABPDPSA-N 0.000 description 9
- ZUDYNBZNVAQABQ-IFZRMHHFSA-N CC1=CC=C(C=C1)S(=O)(=O)OC[C@H]1O[C@H]([C@H]([C@@H]1O)F)N1C=C(C2=C1N=CN=C2NCC1=C(C=C(C=C1)OC)OC)Cl Chemical compound CC1=CC=C(C=C1)S(=O)(=O)OC[C@H]1O[C@H]([C@H]([C@@H]1O)F)N1C=C(C2=C1N=CN=C2NCC1=C(C=C(C=C1)OC)OC)Cl ZUDYNBZNVAQABQ-IFZRMHHFSA-N 0.000 description 9
- JURDMEGTJOURLN-XNWPKKHHSA-N ClC1=CN(C=2N=CN=C(C=21)NCC1=C(C=C(C=C1)OC)OC)[C@H]1[C@H]([C@@H]([C@H](O1)CO)O)F Chemical compound ClC1=CN(C=2N=CN=C(C=21)NCC1=C(C=C(C=C1)OC)OC)[C@H]1[C@H]([C@@H]([C@H](O1)CO)O)F JURDMEGTJOURLN-XNWPKKHHSA-N 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 125000004452 carbocyclyl group Chemical group 0.000 description 9
- 238000007429 general method Methods 0.000 description 9
- 239000007858 starting material Substances 0.000 description 9
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 8
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 238000002953 preparative HPLC Methods 0.000 description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- 238000010898 silica gel chromatography Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 7
- 125000000392 cycloalkenyl group Chemical group 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 6
- FEJUGLKDZJDVFY-UHFFFAOYSA-N 9-borabicyclo(3.3.1)nonane Chemical compound C1CCC2CCCC1B2 FEJUGLKDZJDVFY-UHFFFAOYSA-N 0.000 description 6
- RGRRZCDPYLIRHN-RKCFAAOBSA-N C(C1=CC=CC=C1)(=O)OC[C@H]1O[C@H]([C@H]([C@@H]1OC(C1=CC=CC=C1)=O)F)N1C=C(C2=C1N=CN=C2Cl)Cl Chemical compound C(C1=CC=CC=C1)(=O)OC[C@H]1O[C@H]([C@H]([C@@H]1OC(C1=CC=CC=C1)=O)F)N1C=C(C2=C1N=CN=C2Cl)Cl RGRRZCDPYLIRHN-RKCFAAOBSA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 102100034607 Protein arginine N-methyltransferase 5 Human genes 0.000 description 6
- 101710084427 Protein arginine N-methyltransferase 5 Proteins 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- 239000012230 colorless oil Substances 0.000 description 6
- 125000000753 cycloalkyl group Chemical group 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000003818 flash chromatography Methods 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- RXCSBUSQLFAUBD-BENTYHEHSA-N tert-butyl-[(1R,2R,3S,5R)-5-ethenyl-2-fluoro-3-phenylmethoxycyclopentyl]oxy-diphenylsilane Chemical compound C(C1=CC=CC=C1)O[C@@H]1[C@H]([C@@H]([C@H](C1)C=C)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)F RXCSBUSQLFAUBD-BENTYHEHSA-N 0.000 description 6
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- FUIPENIYMNFFGH-VOTRSWTQSA-N C1(CCCC1)C1=CN(C=2N=CN=C(C=21)NCC1=C(C=C(C=C1)OC)OC)[C@@H]1O[C@@H]([C@H]([C@H]1O)O)COC1=CC=C2C=CC(=NC2=C1)N(C)CC1=C(C=C(C=C1)OC)OC Chemical compound C1(CCCC1)C1=CN(C=2N=CN=C(C=21)NCC1=C(C=C(C=C1)OC)OC)[C@@H]1O[C@@H]([C@H]([C@H]1O)O)COC1=CC=C2C=CC(=NC2=C1)N(C)CC1=C(C=C(C=C1)OC)OC FUIPENIYMNFFGH-VOTRSWTQSA-N 0.000 description 5
- USXARRWVYKWLTC-GSGKNRHYSA-N ClC=1C2=C(N=CN=1)N(C=C2CO)[C@@H]1C[C@@H]([C@H]2OC(O[C@H]21)(C)C)CCC1=CC=C2C=CC(=NC2=C1)NC Chemical compound ClC=1C2=C(N=CN=1)N(C=C2CO)[C@@H]1C[C@@H]([C@H]2OC(O[C@H]21)(C)C)CCC1=CC=C2C=CC(=NC2=C1)NC USXARRWVYKWLTC-GSGKNRHYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 102100031578 N6-adenosine-methyltransferase non-catalytic subunit Human genes 0.000 description 5
- 239000004743 Polypropylene Substances 0.000 description 5
- NDGSCGSEOZGVBG-CTDWIVFPSA-N [(2R,3R,4R,5R)-3,4-dibenzoyloxy-5-(5-bromo-4-chloropyrrolo[2,3-d]pyrimidin-7-yl)oxolan-2-yl]methyl benzoate Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H]1OC(=O)C=1C=CC=CC=1)OC(=O)C=1C=CC=CC=1)N1C=2N=CN=C(C=2C(Br)=C1)Cl)OC(=O)C1=CC=CC=C1 NDGSCGSEOZGVBG-CTDWIVFPSA-N 0.000 description 5
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000010256 biochemical assay Methods 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 5
- 125000001188 haloalkyl group Chemical group 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 5
- 229920001155 polypropylene Polymers 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 101001013582 Homo sapiens N6-adenosine-methyltransferase non-catalytic subunit Proteins 0.000 description 4
- 101000990485 Homo sapiens RNA N6-adenosine-methyltransferase METTL16 Proteins 0.000 description 4
- 101000830183 Homo sapiens tRNA (guanine-N(7)-)-methyltransferase Proteins 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 102100030522 RNA N6-adenosine-methyltransferase METTL16 Human genes 0.000 description 4
- 108010090804 Streptavidin Proteins 0.000 description 4
- 239000008186 active pharmaceutical agent Substances 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 239000012131 assay buffer Substances 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 238000001516 cell proliferation assay Methods 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 238000004020 luminiscence type Methods 0.000 description 4
- VUQUOGPMUUJORT-UHFFFAOYSA-N methyl 4-methylbenzenesulfonate Chemical compound COS(=O)(=O)C1=CC=C(C)C=C1 VUQUOGPMUUJORT-UHFFFAOYSA-N 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- 239000002777 nucleoside Substances 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 229920000136 polysorbate Polymers 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000002285 radioactive effect Effects 0.000 description 4
- 230000035484 reaction time Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 102100025028 tRNA (guanine-N(7)-)-methyltransferase Human genes 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- QOWBXWFYRXSBAS-UHFFFAOYSA-N (2,4-dimethoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C(OC)=C1 QOWBXWFYRXSBAS-UHFFFAOYSA-N 0.000 description 3
- HLVOZSBJQGUPJW-MAUMQABQSA-N (3as,4s,6r,6ar)-6-ethenyl-2,2-dimethyl-4,5,6,6a-tetrahydro-3ah-cyclopenta[d][1,3]dioxol-4-ol Chemical compound O[C@H]1C[C@H](C=C)[C@H]2OC(C)(C)O[C@H]21 HLVOZSBJQGUPJW-MAUMQABQSA-N 0.000 description 3
- 238000004293 19F NMR spectroscopy Methods 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- BUAGRXPPJWUTHT-LZJOCLMNSA-N COC1=C(C=CC(=C1)OC)CNC=1C2=C(N=CN=1)N(C=C2C1=NN(C=C1)C)[C@@H]1C[C@@H]([C@H](C1)O)CO Chemical compound COC1=C(C=CC(=C1)OC)CNC=1C2=C(N=CN=1)N(C=C2C1=NN(C=C1)C)[C@@H]1C[C@@H]([C@H](C1)O)CO BUAGRXPPJWUTHT-LZJOCLMNSA-N 0.000 description 3
- QPOZEQVKRKNFJS-SLBAOYJGSA-N ClC1=CN(C=2N=CN=C(C=21)NCC1=C(C=C(C=C1)OC)OC)[C@H]1[C@H]([C@@H]([C@H](O1)COC1=CC=C2C=CC(=NC2=C1)N(C)CC1=C(C=C(C=C1)OC)OC)O)F Chemical compound ClC1=CN(C=2N=CN=C(C=21)NCC1=C(C=C(C=C1)OC)OC)[C@H]1[C@H]([C@@H]([C@H](O1)COC1=CC=C2C=CC(=NC2=C1)N(C)CC1=C(C=C(C=C1)OC)OC)O)F QPOZEQVKRKNFJS-SLBAOYJGSA-N 0.000 description 3
- YXSQXPSTQSULSK-YNEHKIRRSA-N ClC=1C2=C(N=CN=1)N(C=C2C1CCCC1)[C@H]1C[C@@H]([C@H](O1)CO)O Chemical compound ClC=1C2=C(N=CN=1)N(C=C2C1CCCC1)[C@H]1C[C@@H]([C@H](O1)CO)O YXSQXPSTQSULSK-YNEHKIRRSA-N 0.000 description 3
- GPVRZQVKTMSVKS-GZCUOZMLSA-N ClC=1C2=C(N=CN=1)N(C=C2Cl)[C@H]1[C@H]([C@@H]([C@H](O1)CO)O)F Chemical compound ClC=1C2=C(N=CN=1)N(C=C2Cl)[C@H]1[C@H]([C@@H]([C@H](O1)CO)O)F GPVRZQVKTMSVKS-GZCUOZMLSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WSUFKUUGIGDQEE-MAUMQABQSA-N FC(S(=O)(=O)O[C@H]1C[C@@H]([C@H]2OC(O[C@H]21)(C)C)C=C)(F)F Chemical compound FC(S(=O)(=O)O[C@H]1C[C@@H]([C@H]2OC(O[C@H]21)(C)C)C=C)(F)F WSUFKUUGIGDQEE-MAUMQABQSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- NUGPIZCTELGDOS-QHCPKHFHSA-N N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclopentanecarboxamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CC[C@@H](C=1C=NC=CC=1)NC(=O)C1CCCC1)C NUGPIZCTELGDOS-QHCPKHFHSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 125000001246 bromo group Chemical group Br* 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000000105 evaporative light scattering detection Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 125000002346 iodo group Chemical group I* 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 125000005017 substituted alkenyl group Chemical group 0.000 description 3
- 125000000547 substituted alkyl group Chemical group 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- WIOADUFWOUUQCV-UHFFFAOYSA-N triphenylphosphanium dichloride Chemical compound [Cl-].[Cl-].C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 WIOADUFWOUUQCV-UHFFFAOYSA-N 0.000 description 3
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 3
- VCEMXZUJUHCNIX-AQNXPRMDSA-N (1R,3S,4R)-3-phenylmethoxy-4-(phenylmethoxymethyl)cyclopentan-1-ol Chemical compound C([C@H]1C[C@H](C[C@@H]1OCC=1C=CC=CC=1)O)OCC1=CC=CC=C1 VCEMXZUJUHCNIX-AQNXPRMDSA-N 0.000 description 2
- CUKHVEVYOJENQF-IOSLPCCCSA-N (2r,3r,4s,5r)-2-(5-bromo-4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(Cl)=C2C(Br)=C1 CUKHVEVYOJENQF-IOSLPCCCSA-N 0.000 description 2
- SNAKUPLQASYKTC-AWEZNQCLSA-N (3S)-3-[[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxymethyl]-N-phenylpiperidine-1-carboxamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC[C@@H]1CN(CCC1)C(=O)NC1=CC=CC=C1 SNAKUPLQASYKTC-AWEZNQCLSA-N 0.000 description 2
- ACIYIFAXEVPMOB-ZQARSLAVSA-N (3ar,6r,6ar)-6-ethenyl-2,2-dimethyl-3a,5,6,6a-tetrahydrocyclopenta[d][1,3]dioxol-4-one Chemical compound C=C[C@H]1CC(=O)[C@@H]2OC(C)(C)O[C@@H]21 ACIYIFAXEVPMOB-ZQARSLAVSA-N 0.000 description 2
- UVNPEUJXKZFWSJ-LMTQTHQJSA-N (R)-N-[(4S)-8-[6-amino-5-[(3,3-difluoro-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]pyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1COCC11CCN(CC1)c1cnc(Sc2ccnc3NC(=O)C(F)(F)c23)c(N)n1 UVNPEUJXKZFWSJ-LMTQTHQJSA-N 0.000 description 2
- SQHSJJGGWYIFCD-UHFFFAOYSA-N (e)-1-diazonio-1-dimethoxyphosphorylprop-1-en-2-olate Chemical compound COP(=O)(OC)C(\[N+]#N)=C(\C)[O-] SQHSJJGGWYIFCD-UHFFFAOYSA-N 0.000 description 2
- XAOMFUPJQYNDEG-LBPRGKRZSA-N 1-[(3S)-3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxypiperidin-1-yl]-2-methylpropan-1-one Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)O[C@@H]1CN(CCC1)C(C(C)C)=O XAOMFUPJQYNDEG-LBPRGKRZSA-N 0.000 description 2
- JZSHKZABPPZQLV-UHFFFAOYSA-N 1-[3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]pyridin-2-one Chemical compound NCC1=CC(OC2=CC=CC(=C2)N2C=CC=CC2=O)=NC(=C1)C(F)(F)F JZSHKZABPPZQLV-UHFFFAOYSA-N 0.000 description 2
- XGLVDUUYFKXKPL-UHFFFAOYSA-N 2-(2-methoxyethoxy)-n,n-bis[2-(2-methoxyethoxy)ethyl]ethanamine Chemical compound COCCOCCN(CCOCCOC)CCOCCOC XGLVDUUYFKXKPL-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- SHBHYINHXNTBRP-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(2-methylsulfonylethyl)benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCCS(=O)(=O)C)C=CC=1 SHBHYINHXNTBRP-UHFFFAOYSA-N 0.000 description 2
- XDPCNPCKDGQBAN-UHFFFAOYSA-N 3-hydroxytetrahydrofuran Chemical compound OC1CCOC1 XDPCNPCKDGQBAN-UHFFFAOYSA-N 0.000 description 2
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 2
- ARHQZOGPXNIKNW-UHFFFAOYSA-N 4-chloro-5-cyclopentyl-7h-pyrrolo[2,3-d]pyrimidine Chemical compound C1=2C(Cl)=NC=NC=2NC=C1C1CCCC1 ARHQZOGPXNIKNW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- ZFOJSORAADFLRH-XPNTWCBSSA-N C(C1=CC=CC=C1)O[C@H]1C[C@@H](C[C@@H]1COCC1=CC=CC=C1)N1C=C(C2=C1N=CN=C2Cl)Br Chemical compound C(C1=CC=CC=C1)O[C@H]1C[C@@H](C[C@@H]1COCC1=CC=CC=C1)N1C=C(C2=C1N=CN=C2Cl)Br ZFOJSORAADFLRH-XPNTWCBSSA-N 0.000 description 2
- STOPVRWWTNMJMJ-XPEAMOPSSA-N CC1(O[C@@H]2[C@H](O1)[C@H](C[C@H]2N1C=C(C2=C1N=CN=C2NCC1=C(C=C(C=C1)OC)OC)CO)CCC1=CC=C2C=CC(=NC2=C1)NC)C Chemical compound CC1(O[C@@H]2[C@H](O1)[C@H](C[C@H]2N1C=C(C2=C1N=CN=C2NCC1=C(C=C(C=C1)OC)OC)CO)CCC1=CC=C2C=CC(=NC2=C1)NC)C STOPVRWWTNMJMJ-XPEAMOPSSA-N 0.000 description 2
- PZAZNKPEIMDCKU-OYUWMTPXSA-N CC1=CC=C(C(=O)OC[C@H]2O[C@H](C[C@@H]2OC(C2=CC=C(C=C2)C)=O)N2C=C(C3=C2N=CN=C3Cl)C2CCCC2)C=C1 Chemical compound CC1=CC=C(C(=O)OC[C@H]2O[C@H](C[C@@H]2OC(C2=CC=C(C=C2)C)=O)N2C=C(C3=C2N=CN=C3Cl)C2CCCC2)C=C1 PZAZNKPEIMDCKU-OYUWMTPXSA-N 0.000 description 2
- UWUWUSKXDPLEON-MRJKTFCFSA-N CC1=CC=C(C=C1)S(=O)(=O)OC[C@@H]1[C@H](C[C@@H](C1)N1C=C(C2=C1N=CN=C2NCC1=C(C=C(C=C1)OC)OC)C1=NN(C=C1)C)O Chemical compound CC1=CC=C(C=C1)S(=O)(=O)OC[C@@H]1[C@H](C[C@@H](C1)N1C=C(C2=C1N=CN=C2NCC1=C(C=C(C=C1)OC)OC)C1=NN(C=C1)C)O UWUWUSKXDPLEON-MRJKTFCFSA-N 0.000 description 2
- PVEHTTFSONPJPV-XUVXKRRUSA-N CC1=CC=C(C=C1)S(=O)(=O)OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(C2=C1N=CN=C2Cl)C1CCCC1 Chemical compound CC1=CC=C(C=C1)S(=O)(=O)OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(C2=C1N=CN=C2Cl)C1CCCC1 PVEHTTFSONPJPV-XUVXKRRUSA-N 0.000 description 2
- CHRLUOCQSDZPRB-UHFFFAOYSA-N COC1=C(C=CC(=C1)OC)CN(C1=NC2=CC(=CC=C2C=C1)O)C Chemical compound COC1=C(C=CC(=C1)OC)CN(C1=NC2=CC(=CC=C2C=C1)O)C CHRLUOCQSDZPRB-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- WCSOTFFGPCGMEH-QTKNLHBISA-N ClC=1C2=C(N=CN=1)N(C=C2C1CCCC1)[C@H]1C[C@@H]([C@H](O1)COC1=CC=C2C=CC(=NC2=C1)N(C)CC1=C(C=C(C=C1)OC)OC)O Chemical compound ClC=1C2=C(N=CN=1)N(C=C2C1CCCC1)[C@H]1C[C@@H]([C@H](O1)COC1=CC=C2C=CC(=NC2=C1)N(C)CC1=C(C=C(C=C1)OC)OC)O WCSOTFFGPCGMEH-QTKNLHBISA-N 0.000 description 2
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- PAGCXWAFIYVEGZ-SNUHCZPXSA-N N1(CCC1)C1=NC2=CC(=CC=C2C=C1)CC[C@H]1C[C@H](C[C@@H]1O[Si](C)(C)C(C)(C)C)N1C=C(C2=C1N=CN=C2NCC1=C(C=C(C=C1)OC)OC)C1=NN(C=C1)C Chemical compound N1(CCC1)C1=NC2=CC(=CC=C2C=C1)CC[C@H]1C[C@H](C[C@@H]1O[Si](C)(C)C(C)(C)C)N1C=C(C2=C1N=CN=C2NCC1=C(C=C(C=C1)OC)OC)C1=NN(C=C1)C PAGCXWAFIYVEGZ-SNUHCZPXSA-N 0.000 description 2
- XATIECAACWIYIH-YCGNLMLCSA-N N1(CCC1)C1=NC2=CC(=CC=C2C=C1)CC[C@H]1C[C@H]([C@H]([C@@H]1O)F)N1C=C(C2=C1N=CN=C2NCC1=C(C=C(C=C1)OC)OC)C1=NN(C=C1)C Chemical compound N1(CCC1)C1=NC2=CC(=CC=C2C=C1)CC[C@H]1C[C@H]([C@H]([C@@H]1O)F)N1C=C(C2=C1N=CN=C2NCC1=C(C=C(C=C1)OC)OC)C1=NN(C=C1)C XATIECAACWIYIH-YCGNLMLCSA-N 0.000 description 2
- SUOHZUBSAIJFHD-VHNUMCGNSA-N N1(CCC1)C1=NC2=CC(=CC=C2C=C1)OC[C@@H]1[C@H](C[C@@H](C1)N1C=C(C2=C1N=CN=C2NCC1=C(C=C(C=C1)OC)OC)C1=NN(C=C1)C)O Chemical compound N1(CCC1)C1=NC2=CC(=CC=C2C=C1)OC[C@@H]1[C@H](C[C@@H](C1)N1C=C(C2=C1N=CN=C2NCC1=C(C=C(C=C1)OC)OC)C1=NN(C=C1)C)O SUOHZUBSAIJFHD-VHNUMCGNSA-N 0.000 description 2
- ZCHZOTXCLWRNTF-VJUOEERUSA-N NC=1C2=C(N=CN=1)N(C=C2C1CCCC1)[C@@H]1O[C@@H]([C@H]([C@H]1O)O)COC1=CC=C2C=CC(=NC2=C1)NC Chemical compound NC=1C2=C(N=CN=1)N(C=C2C1CCCC1)[C@@H]1O[C@@H]([C@H]([C@H]1O)O)COC1=CC=C2C=CC(=NC2=C1)NC ZCHZOTXCLWRNTF-VJUOEERUSA-N 0.000 description 2
- QGYDWGDOUSDHOL-GCQDIAHQSA-N NC=1C2=C(N=CN=1)N(C=C2Cl)[C@H]1[C@H]([C@@H]([C@H](O1)COC1=CC=C2C=CC(=NC2=C1)NC)O)F Chemical compound NC=1C2=C(N=CN=1)N(C=C2Cl)[C@H]1[C@H]([C@@H]([C@H](O1)COC1=CC=C2C=CC(=NC2=C1)NC)O)F QGYDWGDOUSDHOL-GCQDIAHQSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- SVJFWOVHIFMWLZ-YVSFHVDLSA-N OC(C1=C([C@H]([C@H](COC(C2=CC=CC=C2)=O)O[C@@H]2Br)[C@@H]2F)C=CC=C1)=O Chemical compound OC(C1=C([C@H]([C@H](COC(C2=CC=CC=C2)=O)O[C@@H]2Br)[C@@H]2F)C=CC=C1)=O SVJFWOVHIFMWLZ-YVSFHVDLSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 244000018633 Prunus armeniaca Species 0.000 description 2
- 235000009827 Prunus armeniaca Nutrition 0.000 description 2
- 229910019020 PtO2 Inorganic materials 0.000 description 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- XNZLGZUMPGXVDF-UHFFFAOYSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-[3-(methoxymethyl)azetidin-1-yl]methanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C=CC=1)C(=O)N1CC(C1)COC XNZLGZUMPGXVDF-UHFFFAOYSA-N 0.000 description 2
- SCJVBILVUYLQPQ-LOYIFYEOSA-N [Si](C)(C)(C(C)(C)C)O[C@@H]1[C@H](C[C@H](C1)N1C=C(C2=C1N=CN=C2NCC1=C(C=C(C=C1)OC)OC)C1=NN(C=C1)C)CO Chemical compound [Si](C)(C)(C(C)(C)C)O[C@@H]1[C@H](C[C@H](C1)N1C=C(C2=C1N=CN=C2NCC1=C(C=C(C=C1)OC)OC)C1=NN(C=C1)C)CO SCJVBILVUYLQPQ-LOYIFYEOSA-N 0.000 description 2
- CUCZWWKTTOLLMC-ZCUZBQTDSA-N [Si](C)(C)(C(C)(C)C)O[C@H]1C[C@@H](C[C@@H]1C#C)N1C=C(C2=C1N=CN=C2NCC1=C(C=C(C=C1)OC)OC)C1=NN(C=C1)C Chemical compound [Si](C)(C)(C(C)(C)C)O[C@H]1C[C@@H](C[C@@H]1C#C)N1C=C(C2=C1N=CN=C2NCC1=C(C=C(C=C1)OC)OC)C1=NN(C=C1)C CUCZWWKTTOLLMC-ZCUZBQTDSA-N 0.000 description 2
- WLLIXJBWWFGEHT-UHFFFAOYSA-N [tert-butyl(dimethyl)silyl] trifluoromethanesulfonate Chemical compound CC(C)(C)[Si](C)(C)OS(=O)(=O)C(F)(F)F WLLIXJBWWFGEHT-UHFFFAOYSA-N 0.000 description 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 2
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 2
- 238000011166 aliquoting Methods 0.000 description 2
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 2
- BVCRERJDOOBZOH-UHFFFAOYSA-N bicyclo[2.2.1]heptanyl Chemical group C1C[C+]2CC[C-]1C2 BVCRERJDOOBZOH-UHFFFAOYSA-N 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229960004424 carbon dioxide Drugs 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 238000012054 celltiter-glo Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 2
- 125000004982 dihaloalkyl group Chemical group 0.000 description 2
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 2
- HPYNZHMRTTWQTB-UHFFFAOYSA-N dimethylpyridine Natural products CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 2
- 238000011773 genetically engineered mouse model Methods 0.000 description 2
- 125000005347 halocycloalkyl group Chemical group 0.000 description 2
- 125000005980 hexynyl group Chemical group 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 125000006682 monohaloalkyl group Chemical group 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 125000006684 polyhaloalkyl group Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 2
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 235000019798 tripotassium phosphate Nutrition 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- WACMQXMZXZTKIV-OLZOCXBDSA-N (1s,2r)-2-(phenylmethoxymethyl)cyclopent-3-en-1-ol Chemical compound O[C@H]1CC=C[C@@H]1COCC1=CC=CC=C1 WACMQXMZXZTKIV-OLZOCXBDSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical group C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- ILWJAOPQHOZXAN-UHFFFAOYSA-N 1,3-dithianyl Chemical group [CH]1SCCCS1 ILWJAOPQHOZXAN-UHFFFAOYSA-N 0.000 description 1
- IMLSAISZLJGWPP-UHFFFAOYSA-N 1,3-dithiolane Chemical compound C1CSCS1 IMLSAISZLJGWPP-UHFFFAOYSA-N 0.000 description 1
- LEOLWMBEILUKMQ-UHFFFAOYSA-N 1-(trityloxymethyl)cyclopentan-1-ol Chemical compound C1(=CC=CC=C1)C(OCC1(CCCC1)O)(C1=CC=CC=C1)C1=CC=CC=C1 LEOLWMBEILUKMQ-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- HEWZVZIVELJPQZ-UHFFFAOYSA-N 2,2-dimethoxypropane Chemical compound COC(C)(C)OC HEWZVZIVELJPQZ-UHFFFAOYSA-N 0.000 description 1
- 125000003562 2,2-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003660 2,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- GEQNZVKIDIPGCO-UHFFFAOYSA-N 2,4-dimethoxyaniline Chemical compound COC1=CC=C(N)C(OC)=C1 GEQNZVKIDIPGCO-UHFFFAOYSA-N 0.000 description 1
- JFTZVYKESKQING-UHFFFAOYSA-N 2-(cyclopenten-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C1=CCCC1 JFTZVYKESKQING-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- XBCVWRJFZFHAKX-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[(1-hydroxycyclobutyl)methyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCC2(CCC2)O)C=CC=1 XBCVWRJFZFHAKX-UHFFFAOYSA-N 0.000 description 1
- SONNQRNOTIAJDS-GFCCVEGCSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[(2R)-2,3-dihydroxypropyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NC[C@H](CO)O)C=CC=1 SONNQRNOTIAJDS-GFCCVEGCSA-N 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 1
- VFTPONHUNNOSKG-UHFFFAOYSA-N 4,5-dichloro-7h-pyrrolo[2,3-d]pyrimidine Chemical compound C1=NC(Cl)=C2C(Cl)=CNC2=N1 VFTPONHUNNOSKG-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- OXLMTRZWMHIZBY-UHFFFAOYSA-N 5-bromo-4-chloro-7h-pyrrolo[2,3-d]pyrimidine Chemical compound ClC1=NC=NC2=C1C(Br)=CN2 OXLMTRZWMHIZBY-UHFFFAOYSA-N 0.000 description 1
- HXFLZWAZSSPLCO-UHFFFAOYSA-N 6,6-dimethylbicyclo[3.1.1]heptyl Chemical group C1[C-]2C([CH2+])([CH2-])[C+]1CCC2 HXFLZWAZSSPLCO-UHFFFAOYSA-N 0.000 description 1
- PEHVGBZKEYRQSX-UHFFFAOYSA-N 6-amino-7-deazapurine Natural products NC1=NC=NC2=C1C=CN2 PEHVGBZKEYRQSX-UHFFFAOYSA-N 0.000 description 1
- QEAYLYXHQWVAOF-UHFFFAOYSA-N 7-bromo-n-methylquinolin-2-amine Chemical compound C1=CC(Br)=CC2=NC(NC)=CC=C21 QEAYLYXHQWVAOF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- MPXKTACSDQDXNY-XQZLXVFMSA-N BrC1=CN(C=2N=CN=C(C=21)NCC1=C(C=C(C=C1)OC)OC)[C@@H]1O[C@@H]([C@H]([C@@H]1F)O[Si](C)(C)C(C)(C)C)C#C Chemical compound BrC1=CN(C=2N=CN=C(C=21)NCC1=C(C=C(C=C1)OC)OC)[C@@H]1O[C@@H]([C@H]([C@@H]1F)O[Si](C)(C)C(C)(C)C)C#C MPXKTACSDQDXNY-XQZLXVFMSA-N 0.000 description 1
- HSHYLYNZXWHCOK-FRJFDASCSA-N C(=C)[C@H]1C[C@H]([C@H]2[C@@H]1OC(O2)(C)C)N1C=C(C2=C1N=CN=C2Cl)C=O Chemical compound C(=C)[C@H]1C[C@H]([C@H]2[C@@H]1OC(O2)(C)C)N1C=C(C2=C1N=CN=C2Cl)C=O HSHYLYNZXWHCOK-FRJFDASCSA-N 0.000 description 1
- XDWPWGPGKDHPAR-IMYHUDGHSA-N C(C1=CC=CC=C1)O[C@@H]1[C@@H]([C@@H]([C@H](C1)C=C)O)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C Chemical compound C(C1=CC=CC=C1)O[C@@H]1[C@@H]([C@@H]([C@H](C1)C=C)O)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C XDWPWGPGKDHPAR-IMYHUDGHSA-N 0.000 description 1
- FXAHJSUOGPKHSG-AUSNRZEJSA-N C(C1=CC=CC=C1)O[C@H]1C[C@@H](C[C@@H]1COCC1=CC=CC=C1)N1C=C(C2=C1N=CN=C2NCC1=C(C=C(C=C1)OC)OC)Br Chemical compound C(C1=CC=CC=C1)O[C@H]1C[C@@H](C[C@@H]1COCC1=CC=CC=C1)N1C=C(C2=C1N=CN=C2NCC1=C(C=C(C=C1)OC)OC)Br FXAHJSUOGPKHSG-AUSNRZEJSA-N 0.000 description 1
- ZYGVRTAGBLIFEJ-OQFWUBAYSA-N C(C1=CC=CC=C1)O[C@H]1C[C@@H](C[C@@H]1COCC1=CC=CC=C1)N1C=C(C2=C1N=CN=C2NCC1=C(C=C(C=C1)OC)OC)C1=NN(C=C1)C Chemical compound C(C1=CC=CC=C1)O[C@H]1C[C@@H](C[C@@H]1COCC1=CC=CC=C1)N1C=C(C2=C1N=CN=C2NCC1=C(C=C(C=C1)OC)OC)C1=NN(C=C1)C ZYGVRTAGBLIFEJ-OQFWUBAYSA-N 0.000 description 1
- OZRYISQOXWXQRS-JONQDZQNSA-N C(C1=CC=CC=C1)O[C@H]1C[C@@H]([C@H]2OC(O[C@H]21)(C)C)C=C Chemical compound C(C1=CC=CC=C1)O[C@H]1C[C@@H]([C@H]2OC(O[C@H]21)(C)C)C=C OZRYISQOXWXQRS-JONQDZQNSA-N 0.000 description 1
- LAKRWYXUCPKELB-HKHUUFBISA-N COC1=C(C=CC(=C1)OC)CNC=1C2=C(N=CN=1)N(C=C2C1=NN(C=C1)C)[C@@H]1C[C@@H]([C@H](C1)O)COC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound COC1=C(C=CC(=C1)OC)CNC=1C2=C(N=CN=1)N(C=C2C1=NN(C=C1)C)[C@@H]1C[C@@H]([C@H](C1)O)COC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1 LAKRWYXUCPKELB-HKHUUFBISA-N 0.000 description 1
- 208000025721 COVID-19 Diseases 0.000 description 1
- ZSTMCGCOXFRRPU-CEDQARPASA-N CS(=O)(=O)O[C@@H]1[C@H]([C@H]([C@H](C1)CCC1=CC=C2C=CC(=NC2=C1)N1CCC1)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)F Chemical compound CS(=O)(=O)O[C@@H]1[C@H]([C@H]([C@H](C1)CCC1=CC=C2C=CC(=NC2=C1)N1CCC1)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)F ZSTMCGCOXFRRPU-CEDQARPASA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- YYBJHJNIGGWMFX-UHFFFAOYSA-M ClC=1C2=C(N=CN=1)N(C=C2C=O)[K] Chemical compound ClC=1C2=C(N=CN=1)N(C=C2C=O)[K] YYBJHJNIGGWMFX-UHFFFAOYSA-M 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- RRSNDVCODIMOFX-MPKOGUQCSA-N Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O Chemical compound Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O RRSNDVCODIMOFX-MPKOGUQCSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 102100034523 Histone H4 Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 description 1
- 101000814246 Homo sapiens tRNA (guanine-N(7)-)-methyltransferase non-catalytic subunit WDR4 Proteins 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- KGAIKXGZLVUMKQ-UHFFFAOYSA-N IC1=CC2=NC(=CC=C2S1)NC Chemical compound IC1=CC2=NC(=CC=C2S1)NC KGAIKXGZLVUMKQ-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 201000005807 Japanese encephalitis Diseases 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 1
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- VQAYFKKCNSOZKM-IOSLPCCCSA-N N(6)-methyladenosine Chemical compound C1=NC=2C(NC)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VQAYFKKCNSOZKM-IOSLPCCCSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- JDUASXKOHYYEBT-UHFFFAOYSA-N N1(CCC1)C1=NC2=CC(=CC=C2C=C1)Br Chemical compound N1(CCC1)C1=NC2=CC(=CC=C2C=C1)Br JDUASXKOHYYEBT-UHFFFAOYSA-N 0.000 description 1
- SLSDRTXRAVFNKJ-COPMUAEDSA-N N1(CCC1)C1=NC2=CC(=CC=C2C=C1)CC[C@@H]1[C@@H]([C@H]([C@H](C1)OCC1=CC=CC=C1)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)F Chemical compound N1(CCC1)C1=NC2=CC(=CC=C2C=C1)CC[C@@H]1[C@@H]([C@H]([C@H](C1)OCC1=CC=CC=C1)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)F SLSDRTXRAVFNKJ-COPMUAEDSA-N 0.000 description 1
- OJLMOTCGLACSOG-HHYCOGPBSA-N N1(CCC1)C1=NC2=CC(=CC=C2C=C1)CC[C@@H]1[C@H]([C@@H]([C@H](C1)O)F)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C Chemical compound N1(CCC1)C1=NC2=CC(=CC=C2C=C1)CC[C@@H]1[C@H]([C@@H]([C@H](C1)O)F)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C OJLMOTCGLACSOG-HHYCOGPBSA-N 0.000 description 1
- RRMQRPASIHSDDX-IVDUZRPMSA-N N1(CCC1)C1=NC2=CC(=CC=C2C=C1)CC[C@@H]1[C@H]([C@@H]([C@H](C1)OCC1=CC=CC=C1)F)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C Chemical compound N1(CCC1)C1=NC2=CC(=CC=C2C=C1)CC[C@@H]1[C@H]([C@@H]([C@H](C1)OCC1=CC=CC=C1)F)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C RRMQRPASIHSDDX-IVDUZRPMSA-N 0.000 description 1
- AVQVJJCHRKDKHC-UHFFFAOYSA-N N1(CCC1)C1=NC2=CC(=CC=C2C=C1)I Chemical compound N1(CCC1)C1=NC2=CC(=CC=C2C=C1)I AVQVJJCHRKDKHC-UHFFFAOYSA-N 0.000 description 1
- VOQTYWGRYYNTQG-UHFFFAOYSA-N N1(CCC1)C1=NC2=CC(=CC=C2C=C1)O Chemical compound N1(CCC1)C1=NC2=CC(=CC=C2C=C1)O VOQTYWGRYYNTQG-UHFFFAOYSA-N 0.000 description 1
- 101710158306 N6-adenosine-methyltransferase catalytic subunit Proteins 0.000 description 1
- 101710081491 N6-adenosine-methyltransferase non-catalytic subunit Proteins 0.000 description 1
- PUAYFPQLLQRSKB-BKSPAHHJSA-N NC=1C2=C(N=CN=1)N(C=C2C1=NN(C=C1)C)[C@@H]1C[C@@H]([C@H](C1)O)CCC1=CC=C2C=CC(=NC2=C1)N1CCC1 Chemical compound NC=1C2=C(N=CN=1)N(C=C2C1=NN(C=C1)C)[C@@H]1C[C@@H]([C@H](C1)O)CCC1=CC=C2C=CC(=NC2=C1)N1CCC1 PUAYFPQLLQRSKB-BKSPAHHJSA-N 0.000 description 1
- OPXOPHGGAFETEJ-HJNVTSSZSA-N NC=1C2=C(N=CN=1)N(C=C2C1=NN(C=C1)C)[C@H]1[C@H]([C@@H]([C@H](O1)CCC1=CC2=NC(=CC=C2S1)NC)O)F Chemical compound NC=1C2=C(N=CN=1)N(C=C2C1=NN(C=C1)C)[C@H]1[C@H]([C@@H]([C@H](O1)CCC1=CC2=NC(=CC=C2S1)NC)O)F OPXOPHGGAFETEJ-HJNVTSSZSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 230000026279 RNA modification Effects 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229910006124 SOCl2 Inorganic materials 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000040856 WT1 Human genes 0.000 description 1
- 108700020467 WT1 Proteins 0.000 description 1
- 201000006449 West Nile encephalitis Diseases 0.000 description 1
- 206010057293 West Nile viral infection Diseases 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 241000907316 Zika virus Species 0.000 description 1
- GCZABPLTDYVJMP-CBUXHAPBSA-N [(2r,3r,4r,5s)-5-acetyloxy-3,4-dibenzoyloxyoxolan-2-yl]methyl benzoate Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H]1OC(=O)C=1C=CC=CC=1)OC(=O)C=1C=CC=CC=1)OC(=O)C)OC(=O)C1=CC=CC=C1 GCZABPLTDYVJMP-CBUXHAPBSA-N 0.000 description 1
- JOAHVPNLVYCSAN-UXGLMHHASA-N [(2r,3r,4s,5r)-3,5-dibenzoyloxy-4-fluorooxolan-2-yl]methyl benzoate Chemical compound O([C@@H]1[C@H]([C@@H]([C@@H](COC(=O)C=2C=CC=CC=2)O1)OC(=O)C=1C=CC=CC=1)F)C(=O)C1=CC=CC=C1 JOAHVPNLVYCSAN-UXGLMHHASA-N 0.000 description 1
- YYVZPZJEMLBIGM-TWMKSMIVSA-N [(2r,3r,4s,5r)-3-benzoyloxy-5-bromo-4-fluorooxolan-2-yl]methyl benzoate Chemical compound C([C@H]1O[C@H](Br)[C@H]([C@@H]1OC(=O)C=1C=CC=CC=1)F)OC(=O)C1=CC=CC=C1 YYVZPZJEMLBIGM-TWMKSMIVSA-N 0.000 description 1
- LJEIALBZIJEQKY-LOYIFYEOSA-N [Si](C)(C)(C(C)(C)C)O[C@@H]1[C@H](C[C@H](C1)N1C=C(C2=C1N=CN=C2NCC1=C(C=C(C=C1)OC)OC)C1=NN(C=C1)C)C=O Chemical compound [Si](C)(C)(C(C)(C)C)O[C@@H]1[C@H](C[C@H](C1)N1C=C(C2=C1N=CN=C2NCC1=C(C=C(C=C1)OC)OC)C1=NN(C=C1)C)C=O LJEIALBZIJEQKY-LOYIFYEOSA-N 0.000 description 1
- LBDOWRUSDJJDCU-YDJVIPEKSA-N [Si](C)(C)(C(C)(C)C)O[C@H]1C[C@@H](C[C@@H]1COC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)N1C=C(C2=C1N=CN=C2NCC1=C(C=C(C=C1)OC)OC)C1=NN(C=C1)C Chemical compound [Si](C)(C)(C(C)(C)C)O[C@H]1C[C@@H](C[C@@H]1COC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)N1C=C(C2=C1N=CN=C2NCC1=C(C=C(C=C1)OC)OC)C1=NN(C=C1)C LBDOWRUSDJJDCU-YDJVIPEKSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000005431 alkyl carboxamide group Chemical group 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000005872 benzooxazolyl group Chemical group 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- MKCBRYIXFFGIKN-UHFFFAOYSA-N bicyclo[1.1.1]pentane Chemical compound C1C2CC1C2 MKCBRYIXFFGIKN-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- KOAVNZURYJRNDR-UHFFFAOYSA-N bromoethene;magnesium Chemical compound [Mg].BrC=C KOAVNZURYJRNDR-UHFFFAOYSA-N 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 150000001669 calcium Chemical class 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 150000005323 carbonate salts Chemical class 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
- 125000004652 decahydroisoquinolinyl group Chemical group C1(NCCC2CCCCC12)* 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- 125000005432 dialkylcarboxamide group Chemical group 0.000 description 1
- 125000005266 diarylamine group Chemical class 0.000 description 1
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 125000006003 dichloroethyl group Chemical group 0.000 description 1
- 125000004774 dichlorofluoromethyl group Chemical group FC(Cl)(Cl)* 0.000 description 1
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 1
- 125000006001 difluoroethyl group Chemical group 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000008846 dynamic interplay Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 201000010284 hepatitis E Diseases 0.000 description 1
- 125000006343 heptafluoro propyl group Chemical group 0.000 description 1
- 125000005241 heteroarylamino group Chemical class 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- JUHDUIDUEUEQND-UHFFFAOYSA-N methylium Chemical compound [CH3+] JUHDUIDUEUEQND-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- FIYYMXYOBLWYQO-UHFFFAOYSA-N ortho-iodylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1I(=O)=O FIYYMXYOBLWYQO-UHFFFAOYSA-N 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- OOFGXDQWDNJDIS-UHFFFAOYSA-N oxathiolane Chemical compound C1COSC1 OOFGXDQWDNJDIS-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- LPNBBFKOUUSUDB-UHFFFAOYSA-M p-toluate Chemical compound CC1=CC=C(C([O-])=O)C=C1 LPNBBFKOUUSUDB-UHFFFAOYSA-M 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940066769 systemic antihistamines substituted alkylamines Drugs 0.000 description 1
- 102100039415 tRNA (guanine-N(7)-)-methyltransferase non-catalytic subunit WDR4 Human genes 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 125000005259 triarylamine group Chemical class 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- KPZSTOVTJYRDIO-UHFFFAOYSA-K trichlorocerium;heptahydrate Chemical compound O.O.O.O.O.O.O.Cl[Ce](Cl)Cl KPZSTOVTJYRDIO-UHFFFAOYSA-K 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000006168 tricyclic group Chemical group 0.000 description 1
- RKBCYCFRFCNLTO-UHFFFAOYSA-N triisopropylamine Chemical compound CC(C)N(C(C)C)C(C)C RKBCYCFRFCNLTO-UHFFFAOYSA-N 0.000 description 1
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 1
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000001173 tumoral effect Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962923936P | 2019-10-21 | 2019-10-21 | |
| US62/923,936 | 2019-10-21 | ||
| PCT/IB2020/001135 WO2021079196A2 (en) | 2019-10-21 | 2020-10-20 | Mettl3 modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2020372002A1 true AU2020372002A1 (en) | 2022-05-26 |
Family
ID=73856560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020372002A Abandoned AU2020372002A1 (en) | 2019-10-21 | 2020-10-20 | Mettl3 modulators |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230027361A1 (https=) |
| EP (1) | EP4048674A2 (https=) |
| JP (1) | JP2022553077A (https=) |
| CN (1) | CN115298179A (https=) |
| AU (1) | AU2020372002A1 (https=) |
| WO (1) | WO2021079196A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022074391A1 (en) * | 2020-10-08 | 2022-04-14 | Storm Therapeutics Limited | Compounds inhibitors of mettl3 |
| CN113234079B (zh) * | 2021-04-30 | 2022-02-01 | 上海湃隆生物科技有限公司 | 用作prmt5抑制剂的核苷类似物 |
| CN114032311A (zh) * | 2021-12-24 | 2022-02-11 | 山东大学齐鲁医院 | Mettl3在aml化疗耐药性中的应用 |
| CN118660890A (zh) * | 2022-02-11 | 2024-09-17 | 西藏海思科制药有限公司 | 一种mettl3抑制剂及组合物及其在医药上的应用 |
| CN115850280B (zh) * | 2022-12-08 | 2024-07-05 | 南京康立瑞生物科技有限公司 | 一种抗病毒药恩替卡韦中间体n4的制备方法 |
| CN120731203A (zh) | 2023-01-20 | 2025-09-30 | 艾匹克治疗公司 | 作为mettl3抑制剂的哌啶衍生物 |
| AU2024244637A1 (en) | 2023-03-30 | 2025-10-16 | Aqemia | Novel mettl3 inhibitors and use thereof in therapy |
| WO2025049624A1 (en) * | 2023-08-29 | 2025-03-06 | Purdue Research Foundation | Prodrugs of nicotinamide n-methyltransferase (nnmt) inhibitors and uses thereof |
| WO2025106014A1 (en) * | 2023-11-14 | 2025-05-22 | Engine Biosciences Pte. Ltd. | Compounds and methods for pkmyt1 inhibition |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI870767B (zh) * | 2015-08-26 | 2025-01-21 | 比利時商健生藥品公司 | 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物 |
| WO2018065365A1 (en) * | 2016-10-03 | 2018-04-12 | Janssen Pharmaceutica Nv | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors |
| EP3939986A1 (en) * | 2017-08-09 | 2022-01-19 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| JP2021505583A (ja) * | 2017-12-05 | 2021-02-18 | エンジェクス ファーマシューティカル インコーポレイテッド | Ｐｍｒｔ５阻害剤としての複素環式化合物 |
| MA55556A (fr) * | 2019-04-02 | 2022-02-09 | Aligos Therapeutics Inc | Composés ciblant prmt5 |
-
2020
- 2020-10-20 EP EP20862016.1A patent/EP4048674A2/en not_active Withdrawn
- 2020-10-20 US US17/770,708 patent/US20230027361A1/en not_active Abandoned
- 2020-10-20 AU AU2020372002A patent/AU2020372002A1/en not_active Abandoned
- 2020-10-20 WO PCT/IB2020/001135 patent/WO2021079196A2/en not_active Ceased
- 2020-10-20 CN CN202080088790.7A patent/CN115298179A/zh active Pending
- 2020-10-20 JP JP2022523855A patent/JP2022553077A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN115298179A (zh) | 2022-11-04 |
| WO2021079196A3 (en) | 2021-07-01 |
| US20230027361A1 (en) | 2023-01-26 |
| WO2021079196A2 (en) | 2021-04-29 |
| JP2022553077A (ja) | 2022-12-21 |
| WO2021079196A9 (en) | 2022-07-14 |
| EP4048674A2 (en) | 2022-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020372002A1 (en) | Mettl3 modulators | |
| ES2619125T3 (es) | Compuestos heterocíclicos fusionados como inhibidores de proteína cinasa | |
| CA2804840C (en) | Methods and compounds for treating paramyxoviridae virus infections | |
| CA2861795C (en) | Pyrazoloquinoline derivative | |
| EP3145512B1 (en) | Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors | |
| EP4129996A1 (en) | Novel aminopyrimidine egfr inhibitor | |
| EP4516779A1 (en) | Pyrimidine compound, method for preparing same, and pharmaceutical use thereof | |
| EP3048105A1 (en) | Compound inhibiting activities of btk and/or jak3 kinases | |
| KR20170137165A (ko) | 인돌아민 및/또는 트립토판 2,3-디옥시게나아제로서 신규한 5 또는 8-치환된 이미다조[1,5-a]피리딘 | |
| EP4048670A1 (en) | Mettl3 modulators | |
| TW201311692A (zh) | 三唑並嘧啶類衍生物、其製備方法及其在醫藥上的應用 | |
| CN103582638A (zh) | 杂芳基并嘧啶类衍生物、其制备方法和用途 | |
| KR20150127205A (ko) | Ship1 조절제 및 그와 관련된 방법 | |
| EP4229067A1 (en) | Mettl3 modulators | |
| CN119013030A (zh) | Cdk4/6激酶的抑制剂 | |
| CN113004282B (zh) | 取代的炔基杂环化合物 | |
| EP4011865A1 (en) | Bridged heterocyclyl-substituted pyrimidine compound, preparation method therefor, and pharmaceutical use thereof | |
| CN113880842B (zh) | 取代的炔基杂环化合物 | |
| WO2019080724A1 (zh) | 核苷磷酸类化合物及其制备方法和用途 | |
| TW202227418A (zh) | 一種雜環衍生物及其在醫藥上的應用 | |
| CN117486885B (zh) | 吡唑并嘧啶类化合物的用途 | |
| WO2025041076A1 (en) | Bicyclic compounds as cdk inhibitors | |
| WO2025078995A1 (en) | Substituted 6-(pyrimidin-4-yl)quinoline compounds as cyclin dependent kinase inhibitors | |
| WO2025231112A1 (en) | Sik2 modulators and uses thereof | |
| CN119285627A (zh) | 一种靶向pde4b酶的化合物及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |